# Prevention of Cefoperazone-induced Coagulopathy

> **NCT05742295** · PHASE4 · COMPLETED · sponsor: **Helwan University** · enrollment: 56 (actual)

## Conditions studied

- Antibiotic Side Effect

## Interventions

- **DRUG:** Vitamin K

## Key facts

- **NCT ID:** NCT05742295
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-25
- **Primary completion:** 2023-10-05
- **Final completion:** 2023-10-05
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05742295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05742295, "Prevention of Cefoperazone-induced Coagulopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05742295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*